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Transforming growth factor ß (TGFß) is a multifunctional growth regulatorwith
diverse biological effects, including promotion and inhibition offibroblastic and ep-
ithelial cell growth, respectively (1, 2), chemotaxis ofdermal fibroblasts and mono-
cytes (3, 4), facilitationofextracellular matrix remodelingby fibroblastic cells (5-7),
and effects on proliferation and function ofT and B lymphocytes (8-10). These cel-
lularresponses appear pertinentto developmentand/or maintenance ofthe synovial
panmus in inflammatory arthritis. Furthermore, subcutaneous injection ofpurified
TGFP into newborn mice resultsina multicellular response over 48-72 h (11), which
is histologically similar to the synovial panmus seen in rheumatoid arthritis (RA).
These findings led us to examine synovial effusions for the presence of TGFß.
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SynovialFluids.
￿
Synovial fluids from the knees of 16 patients seen in the Vanderbilt University
Rheumatology Clinic were collected by needle aspiration into heparin-free plastic syringes.
Diagnoses determined by a rheumatologist included nine patients with RA, four with os-
teoarthritis, two with gout, and one patient with avascu1ar necrosis.
Most fluids were routinely centrifuged at 1,200 g for 10 min at 4°C to remove cells. Some
fluids were subjected to a more rigorous collection procedure involvingcentrifugation in plastic
tubes at 5,000 g in a Sorvall high-speed centrifuge for 20 min, in order to minimize the possi-
bility of contamination with platelet products released in vitro. The cell- and platelet-free
supernatants were then collected with a glass pipette that was left in the tube at 37°C . Clotted
material that formed around the glass pipette was discarded. The fluids were stored at - 70°C
until assay.
Assaysfor 7GF--ß.
￿
A radioreceptor assay for TGFß was performed using a previously de-
scribed procedure (12). Briefly, AKR-2B fibroblasts were plated in six-well culture plates at
1-2 x 105 cells per well using McCoy's 5A medium with 5% FCS. The next day, cells were
washed three times with PBS and incubated for 2 h in the presence of 0.25 ng of '2'ITGFp
in 1.0 ml of binding medium, with or without further additions. Nonspecific binding was
determined by the addition of 1 gg of 50% pure unlabeled TGFP.
After a 2-h incubation at room temperature with rocking, the cells were washed, released
from the plate with collagenase, and cell-bound 1251TGF-ß was measured in a gamma
counter. Results were expressed as nanograms per milliliter TGF0 calculated from a stan-
dard curve (see Fig. 1). The concentrations of TGFß-competing activity in synovial fluids
(Table I) were derived from triplicate determinations at a final dilution that would yield a
40-60% inhibition of binding.
Two cell lines were also used in soft agar assays for TGF-ß. AKR-2B cells were assayed
in the presence of serum as previously described (13). Base layers of 0.8% agar in McCoy's
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5A medium supplemented with 10% FCS were prepared in 35-mm culture dishes. Upper
layers of 0.4% agar in McCoy's 5A medium contained 10% FCS, 7.5 x 10j cells, and the
synovial fluid to be tested. The number of colonies >50 gm was quantitated after 7 d using
an image analyzer (Omnicon FAS III; Bausch & Lomb, Inc., Rochester, NY).
Soft agar assays were also performed in 24-well plates with NRK-49F indicator cells in
a highly sensitive serum-free assay (>2 pg TGF0) (14). Supplemental growth factors (see Fig.
2 legend), human high density lipoprotein (HDL), retinoic acid, and the samples to be tested
were added simultaneously to a 0.3 ml overlayer of basal medium immediately after plating
the cells. To evaluate the ability of specific antisera to block colony formation induced by
TGF-por acid-treated synovial fluid, 20 ltg of normal rabbit IgG or 20 ug IgG isolated from
antisera against TGF-P (15) were added to the upper medium layer (simultaneously with other
factors). After 10 d incubation at 37°C, the colonies were fixed and stained with 10% formal-
dehyde/0.01% crystal violet, counted with the aid of a dissecting microscope, and the efficiency
of colony formation was expressed as the percentage of plated cells forming colonies >50 ltm
in diameter.
AcidActivation ofLatent TGF-/3.
￿
TGF-P is known to exist in two forms, an active form that
interacts directly with cell surface receptors and a less well characterized"latent" form(s) that
can be activated by acidification, proteolysis, and other biochemical methods (12). Six ran-
domly selected fluids were acid treatedby dialysis of a 1.0-ml aliquot in 1 M acetic acid (pH
3.6) for 18 h at 25°C. The resultant precipitate was removed by centrifugation for 5 min
at 12,000 g. The supernatant was then dialyzed against 10 mM acetic acid and assayed for
TGF-0. Equivalent aliquots of 10 mM acetic acid were shown not to affect the assays.
Results
A dose-response curve for the radioreceptor competition assay that was used to
quantitate TGF0 activity in untreated and acid-activated synovial effusions is shown
in Fig. 1. In all synovial fluid samples examined, dose-response curves were observed
that were similarto that seen when purified unlabeled TGF0 was added as compet-
itor. Thus, despite their complex composition, the synovial fluids appear to have
capacity to compete directly for receptor binding, similarly to purified TGF-0.
The mean levels of active TGF-P in untreated synovial fluids (Table I) were 10.1
ng/ml for RA fluids and 3.8 ng/ml for osteoarthritis fluids, a statistically significant
difference (p < 0.005). Two gout fluids showed a mean level of 8.0 ng/ml, and a
noninflammatory fluid (white blood cells, <200) obtained from a patient with avas-
cu1ar necrosis showed no TGF0 activity detectable by the radioreceptor assay (<1
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FIGURE 1 . Competition of untreated and
acid-activated synovial fluids and purified
TGFp in areceptor bindingassayperformed
with cultured AKR2B fibroblasts. Percent in-
hibition represents the reduction in specific
binding, observed when cells were incubated
for2 h at 25°C, in thepresence of 125ITGFp
(0.25 ng/ml) and the indicatedamounts(ng)
ofunlabeledTGF0 (")or aliquots (g1) ofsy-
novial fluid preparations. All illustrated sy-
novial fluids were from patients with diagnoses
ofRA. One fluid, RA#1 (ACID), was also as-
sayed after acid activation as described in o
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TABLE I
Mean Levels of TGF-0 (ng/ml) in Synovial Effusions by Radioreceptor Assay
Transient acidification before assay (Materials and Methods) .
1 p < 0.005 between these two groups .
9 Determined by NRK-49F colony formation assay .
ng/ml) . Acid activation resulted in increased TGF-0 activity in all six fluids tested,
indicating the likelihood of a latent TGFß pool .
To confirm the presence of the TGF-ß-like activity using an additional assay, five
fluids were examined for the capacity to promote soft-agar colony formation ofAKR2B
and NRK-49F fibroblasts . Each of the fluids examined was found to promote soft-
agar colony formation by the indicator cell lines in a dose-dependent manner (data
not shown) . Colony formation ofNRK-49F cells induced by each offive fluids exam-
ined required exogenous epidermal growth factor in this serum-free assay, as has
been previously described for TGF-0 (14) . The use of this extremely sensitive assay
enabled recognition of 0.8 ng/ml TGF-ß for the acid activated avascu1ar necrosis
fluid shown in Table I .
The TGF-0 activity present in acid-activated synovial fluid, at a dose equivalent
to 8 pg TGF-ß, was completely abolished when 20 gg of antiTGF-ß IgG, but not
an equivalent amount ofnormal rabbit IgG, was included in the assay (Fig . 2) . Three
synovial fluids from RA patients examined in this manner gave similar results .
Since TGFP is normally stored in platelets and released upon platelet lysis, it
appeared of value to examine whether any portion of the observed TGFß activity
in routinely collected cell-free fluids may have been derived from in vitro platelet
lysis . Therefore, replicate aliquots of two randomly chosen synovial fluids were pre-
FIGURE 2 .
￿
Soft-agar colony formation by acid
activated and untreated synovial fluids and
inhibition by antibody againstTGFp . NRK-
49F cells were plated in soft-agar in a serum-
free medium supplemented with insulin (10
Wg/ml), transferrin (5 jig/ml), HDL (100 jig/
ml), retinoic acid (100 ng/ml), and epidermal
growth factor (50 ng/ml) and additions were
made as shown in the Figure . 10% FCS in-
duced86% ofthe cells to form colonies in this
experiment . The background level (BKG)
without additions was9°Jo of FCS control. The
response to 10 pg TGF-0 and an aliquot (1 lil)
of acid-activated synovial fluid equivalent to
8 pg TGF-0 (RAI) were completely blocked
by 20 lig/ml ofanti TGFp IgG (+Ab) but not
by 20 ug/ml ofIgG from normal rabbit serum
(+NRS) . The responses to aliquots ofanother
(RA2) acid-activated and untreated (RAT)
fluid are also illustrated.
Diagnosis
Number of
specimens Untreated
Acid
activation`
Rheumatoid arthritis 9 10.11 37 .5
Osteoarthritis 4 3.81 12 .0
Gout 2 8.0 21 .0
Avascu1ar necrosis 1 <1 .0 0.89294
￿
FAVA ET AL.
￿
BRIEF DEFINITIVE REPORT
TABLE II
Comparison of Low Speed and High Speed Centrifugation of Synovial Fluids
Percent inhibition in radioreceptor assay
Sample
￿
Low speed
￿
High speed
1
￿
15.2
￿
10 .9
2
￿
34.8
￿
33 .6
50 wl of each sample added to assay. Results are mean values of triplicate deter-
minations.
pared under routine and more stringent conditions designed to eliminate platelet
contamination (see Materials and Methods). There was essentially no difference in
the amount of TGFß detected after either method of preparation for the two fluids
examined (Table II).
Discussion
The presence of TGF-ß-like activity in inflammatory synovial fluids suggests that
this multifunctional mediator may participate in the initiation or maintenance of
synovitis, or may appear as the consequence of a tissue response to the presence
of other cytokines. It is possible that the competition observed in the radioreceptor
assay may result in part from TGFß binding proteins present in whole synovial fluids.
However, the demonstration of activity in soft-agar colony formation, of immuno-
logical neutralization of biological activity, and activation of latent forms, would
strongly suggest that TGF-ß activity is present in synovial fluid .
Several cellular responses known to be mediated by TGFp might play a role in
the development and/or maintenance of inflammatory synovitis, including: (a) the
capacity to stimulate chemotaxis and, therefore, local "accumulation" of fibroblasts
(3); (b) promotion of collagen, proteoglycan, and fibronectin production by fibro-
blastic cells (5-7), which could contribute to elevated levels of atypical isoforms of
fibronectin that have been reported to accumulate in RA joint fluids (16, 17); (c)
chemotaxis ofmonocytes (4); and (d) antiproliferative or immunosuppressive effects
on T cells (8-10), which may account in part for the reduced in vitro response of
isolated synovial fluid lymphocytes to proliferation stimuli (18).
The TGFß found in synovial fluid may be delivered from T lymphocytes, B lym-
phocytes, and/or activated macrophages, all of which have been shown to produce
TGF-ß (8, 9, 19), platelets lysed at sites of microvascular injury, and synovial cells
themselves (20). Activation of latent TGFR-like activity can be effected by proteases
such as plasmin and cathepsin D (12). If present in the synovial panmus, such "ac-
tivating" proteases could increase levels of active TGFß locally. Thus, alterations
in the levels of such proteases and/or their inhibitors in the synovial panmus could
act in concert with latent TGF0 production by endogenous or infiltrating cell types
in sustaining the complex cellular activities observed in this lesion. Further investi-
gation into the role of TGFß in the development of synovitis may provide impor-
tant clues to the etiopathogenesis of the inflammatory arthritides.
Summary
We have evaluated the possible involvement of TGFß in rheumatoid arthritis by
assay of 16 cell-free synovial fluids for the presence of its active and "latent" forms.FAVA ET AL.
￿
BRIEF DEFINITIVE REPORT
￿
295
Evidence has been obtained for TGF0-like activity in synovial effusions by four
criteria: (a) TGF0 receptor competition, (b) soft-agar colony formation of AKR
2B and NRK-49F indicator cells, (c) immunological neutralization ofthe biological
activity, and (d) biochemical activation of a latent form.
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